ResMed's stock valuation and performance have been at the center of attention recently.
CEO Michael Farrell sold 4,991 shares after exercising his options, leading meanwhile, leading to questions regarding management's faith in its valuation. Moreover, stock trading has been consistently going down, with a 5-day losing spree causing a 8.8% slide. Notably, Citigroup lowered their price target for
RMD and maintained it with a Buy rating. Despite these bearish indicators, there is some optimism surrounding the company,
ResMed has been upgraded to Buy due to recent share price weakness and strong earnings. The company also has been attracting new investments; Runnymede Capital Advisors acquired 4,837 shares, while Element Squared LLC bought 6,067
RMD shares.
ResMed also reported strong Q2 2026 growth earnings and revenues, bolstering the confidence of analysts; Q1 earnings also beat estimates. However, certain investors have reduced their holdings in RMD, such as Pacific Point Advisors and Spire Wealth Management. Moreover, bith
CEO and
CFO sold shares, causing some worry among investors. Despite a slide in market value the company's solid fundamentals are expected to support continued growth.
Resmed RMD News Analytics from Fri, 01 Aug 2025 07:00:00 GMT to Sat, 11 Apr 2026 12:05:43 GMT -
Rating -5
- Innovation 7
- Information 4
- Rumor -2
